Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Mocetinostat
Drugstatus Investigational
Drugbank ID DB11830(DB05666)
Checkpoints NA
Signature Type Protein
Signature HELIOS
Official Symbol IKZF2
Mode of action TRAN_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Treatment of cells with mocetinostat at concentrations of 500 nM or below had little effect on the relative percentage of live CD3 + cells or CD4 + CD127-CD25 + Treg cells. Within the CD4 + CD127-CD25 + population, however, the expression of both FOXP3 and HELIOS, two established markers of Treg polarization and suppressive function, were significantly decreased by 250 nM mocetinostat treatment . FOXP3 expression was almost completely abrogated with 250 nM mocetinostat.
PMID 29124315
Title The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy